TNF and depressive symptom measurement: The CH–BS drug pair can reduce the generation of peroxidation products and down-regulate NLRP3 inflammasome expression, IL-1β, IL-6, and tumor necrosis factor (TNF)-α secretion to treat depression by combating inflammatory response and oxidative stress damage [31].